Equity Overview
Price & Market Data
Price: $17.64
Daily Change: -$0.98 / 5.56%
Daily Range: $17.32 - $18.80
Market Cap: $273,240,064
Daily Volume: 164,454
Performance Metrics
1 Week: 3.76%
1 Month: -3.66%
3 Months: -17.42%
6 Months: -10.05%
1 Year: 1.91%
YTD: -14.37%
Company Details
Employees: 107
Sector: Health technology
Industry: Biotechnology
Country:
Details
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreements with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.